. Synthesis, antimycobacterial and cytotoxic evaluation of substituted isoindoline-1,3-dione-4-aminoquinolines coupled via alkyl/amide linkers. RSC Advances, Royal Society of Chemistry, 2019, 9 (15) A series of secondary amine-substituted isoindoline-1,3-dione-4-aminoquinolines were prepared via microwave heating and assayed for their anti-mycobacterial activities. The compound with a butyl chain as a spacer between the two pharmacophores and piperidine as the secondary amine component on the isoindoline ring was the most potent and non-cytotoxic among the synthesized compounds, exhibiting a minimum inhibitory concentration (MIC 99 ) of 6.25 mg mL À1 against Mycobacterium tuberculosis.
Introduction
Tuberculosis (TB) is a global pandemic caused by the single infectious agent Mycobacterium tuberculosis. TB has been a scourge to mankind for thousands of years and roughly more than one third of the world's population is latently infected.
1 In 2016, there were 10.4 million new cases of TB diagnosed with approximate mortality of 1.3 million among HIV-negative and an additional 374 000 deaths among HIV-positive people, mostly in developing countries. 2 According to the Revised National Tuberculosis Control Program (RNTCP), India accounts for one fourth of the global TB burden with 1.75 million TB patients, including data from both the public and private health sectors, while 33 820 drug-resistant TB patients are noted additionally. 3 Increasing cases of multidrug-resistant (MDR) TB and extensively drug-resistant (XDR) TB all over the world is hindering current TB treatment, 4 which includes the rst-line drugs isoniazid (INH), rifampicin (RIF), pyrazinamide, ethambutol, and streptomycin, and the second line drugs, aminoglycosides, polypeptides, uoroquinolones, thioamides, cycloserine and terizidone. 5, 6 The emergence of resistant strains warrants the urgent search for faster-acting, less harmful, more efficient drug candidates.
The quinoline core has received recent attention as it is one of the active key building blocks of many drugs. Bedaquilinea diarylquinoline -was recently approved by Food and Drug Administration (FDA) and European Medicine Agency (EMA) for treating MDR-TB patients. [7] [8] [9] However, the drug comes with a black-box warning, which includes the risk of cardiac (QT prolongation) and hepatic dysfunction and heightened risk of mortality. 10 Meoquine, an orally administered drug, is another quinoline derivative known for potent anti-tubercular activity. [11] [12] [13] [14] [15] Remarkably, numerous derivatives of meoquine were reported to have good antibacterial and anti-mycobacterial activities.
16,17
Isoindoline-1,3-dione and its derivatives were shown to possess interesting biological properties 18 against a wide panel of diseases and conditions, such as angiogenic disease, 19 inammation, 20 cancer, 21, 22 Parkinson's, 23 leprosy, AIDS and multiple myeloma (MM); as COX inhibitors; antidepressants and histone deacetylase inhibitors. 24 Synthesis of conjugates of the isoindoline-1,3-dione subunit with different active moieties afforded active antimicrobials against Mycobacterium leprae and M. tuberculosis.
25
A recent report from our lab highlighted the antimycobacterial potential of isoindoline-1,3-dione-4-aminoquinolines, exhibiting comparable activity with ethionamide and cephalexin (Fig. 1) . 26 In continuation of our efforts,
27
we present herein the synthesis and anti-mycobacterial activities of secondary amino-substituted isoindoline-1,3-dione-4-aminoquinolines. The spacer length between two pharmacophores as well as the secondary amine functionality at the C4/C5 position of isoindoline-1,3-dione was meticulously altered for analysing the structure-activity relationship (SAR).
Results and discussion

Synthetic chemistry
For the synthesis of the desired isoindoline-1,3-dione-4-aminoquinolines with the secondary amine functionality at the C-4/C-5 position, microwave heating was attempted, as the reactions were sluggish when carried out under conventional heating. The microwave assisted reaction between 3-uoro-phthalic anhydride 1a, N-(7-chloroquinolin-4-yl)diamine 2a 28 and piperidine was chosen as model reaction. Different solvents viz. DMF, DMSO and NMP were screened, both for the singlepot as well as for the step-wise synthesis and the results are provided in Scheme 1. As evident, the single pot synthesis gave the desired scaffold 4a, albeit in moderate yields, when compared to the step-wise process. The solvent choice seems to be crucial and better yields were observed by heating in NMP because of its polar aprotic nature and ease of removal during purication procedure. Best results obtained via either heating in single pot synthesis at 160 C for 5 min (70% yield) or in stepwise synthesis by heating at 140 C for 2 min for step 1 and then at 160 C for 2 min for step 2 (89% yield).
Having optimized the reaction conditions, the scope of the developed strategy was then explored for the synthesis of a series of C-4/C-5 secondary amine linked isoindoline-1,3-dione-4-aminoquinolines 4b-4t following the stepwise microwave synthesis (Scheme 2). The structure assignment was done on the basis of spectral data and analytical evidences. For example, the compound 4s exhibited a molecular ion peak at m/ z 508. 2084 C NMR spectrum along with methylenes at d 25.5, 26.5, 37.2 and 42.8 and piperazine carbons at d 47.6 and 52.4, as corroborated by the 13 C NMR (DEPT) spectrum, validated the assigned structure. For the synthesis of conjugates 7a-r, amide coupling of 6 with N-(7-chloroquinolin-4-yl)diamine 2 was done using amide coupling reagents EDCHOBt at room temperature. Further, C-5 ouro substituted conjugates 7m-r were reacted with different secondary amines under microwave heating resulted in the formation of desired conjugates 8a-r in good to excellent yields (Scheme 3). Spectral data and analytical evidences were used to assign the structure to the synthesized conjugates.
In vitro anti-mycobacterial evaluation
The synthesized scaffolds were assayed for their antimycobacterial activities against M. tuberculosis mc 2 6230 and the result are enlisted in Table 1 . As evident, all the synthesized compounds were not as active as isoniazid, but some of them showed promising activities. A closer analysis of Table 1 showed the dependence of activity on the nature of linker between two pharmacophores, the nature of substituent at C-4/C-5 position of isoindoline-1,3-dione as well as the linker used as spacer. Cytotoxic studies of all the synthesized compounds were also carried out against Vero cells so as to conrm whether the observed activities were due to their inherent antimycobacterial efficacy or cytotoxicity (Table 1 , Fig. 2 ).
Among isoindoline-1,3-dione-4-aminoquinolines linked via alkyl chain 4a-t, the replacement of uoro-substituent (compound I, Fig. 1 ) with secondary amine on isoindoline-1,3-dione ring, not only improved the anti-TB activity but also reduced their cytotoxicity, which were in the range of 5.03-20.92 mg mL À1 . 26 Introduction of a piperidine ring at the C-4/C-5 , for all three compounds, but also increased their respective cytotoxicity.
Among the amide tethered isoindoline-1,3-dione-4-aminoquinoline 7a-r, although a decrease in antimycobacterial activity has been observed in general, the compounds were non-cytotoxic in nature. Among the scaffold having n ¼ 1 (Glycine), the compound 7d (R ¼ H, n ¼ 8) and 7m (R ¼ F, n ¼ 2) displayed better activity proles compared to the other members of the series with MIC of 12.5 and 6.25 mg mL
À1
respectively. The introduction of b-alanine and g-aminobutyric acid showed more or less similar activity proles with low cytotoxicity. The introduction of secondary amine functionality among the amide-linked series resulted in considerable loss of anti-mycobacterial activities except for the compound 8b which was non-cytotoxic and exhibited a MIC of 12.5 mg mL À1 . The generalized SAR of the synthesized isoindoline-1,3-dione-4-aminoquinolines (both the alkyl chain as well as amide-core tethered) for their anti-mycobacterial activity against mc 2 6230 strain of M. tuberculosis and cytotoxicity against Vero cells is depicted in Fig. 3 .
Conclusion
In conclusion, the present describes the microwave-promoted synthesis of a series of C-4/C-5 secondary amine substituted isoindoline-1,3-dione-4-aminoquinolines coupled via alkyl/ amide core as linker. The synthesized scaffolds were evaluated for their anti-mycobacterial proles against the M. tuberculosis mc 2 6230 strain while cytotoxicity was determined against Vero cells. The compound 4g with an optimum combination of piperidine as the secondary amine at C-5 position and a butyl chain as spacer proved to be non-cytotoxic with a MIC 99 of 6.25 mg mL À1 .
Experimental section
General
Veego Precision Digital Melting Point apparatus (MP-D) was used for the determination of melting points which are uncorrected. 1 H NMR spectra were recorded in deuterated chloroform (CDCl 3 )/DMSO-d 6 using Bruker 500 (500 MHz) and Jeol 400 (400 MHz) spectrometers while TMS is used as internal standard.
Microwave reactions were performed in a Biotage® Initiator+ instrument using sealed 2-5 mL process vials. Reaction times refer to irradiation time at the target temperature, not the total irradiation time. General procedure for the preparation of C-4/C-5 secondary amine substituted isoindoline-1,3-dione-4-aminoquinolines (4a-t)
To a microwave reaction vial was added a solution of C-3/C-4 uoro-phthalic anhydride (1.0 mmol) in 0.5 mL of NMP (Nmethylpyrrolidin-2-one) and 4-aminoquinoline-diamines (1.0 mmol). Aer sealing with a PTFE cap, the vessel was heated to 130 C for 2 min in the microwave reactor. Aer accomplishment of the rst step, as obvious from TLC, secondary amine (1.2 mmol) was added in the same reaction vial. The reaction mixture was again heated at 160 C for 5 min in the microwave reactor and the completion was ascertained using TLC. Aer completion, the contents were poured in water (20 mL) resulting in the precipitation of the desired product. The obtained product was ltered and re-crystallized using absolute ethanol. 
General procedure for synthesis of amide linked substituted isoindoline-1,3-dione-4-aminoquinolines (7a-r, 8a-r)
Synthesis of C-5 substituted 2-(1,3-dioxoisoindolin-2-yl)acetic acid/3-(1,3-dioxoisoindolin-2-yl)propanoic acid/4-(1,3-dioxoisoindolin-2-yl)butanoic acid (6): C-4 substituted phthalic anhydride (1 mmol), amino acids (1.2 mmol) and triethylamine (Et 3 N) (1.2 mmol) were mixed in toluene and the reaction mixture was reuxed for 6 h. The progress of the reaction was monitored by thin layer chromatography (TLC). Toluene was evaporated under reduced pressure and the solid residue was stirred with 1 N-HCl in ice-cold water. The resulted white powder was ltered, dried and used for subsequent step without any purication.
Synthesis of C-5 substituted N-(2-((7-chloroquinolin-4-yl)amino) alkyl)-2-(1,3-dioxoisoindolin-2-yl)alkylamides (7a-r)
1.0 mmol of C-5 substituted (1,3-dioxoisoindolin-2-yl)acetic acid, N-ethyl-N-dimethylaminopropyl carbodiimide (EDC) (1.1 mmol), hydroxybenzotriazole (HOBt) (1.2 mmol) and N,N-diisopropylethylamine (2.0 mmol) were mixed in minimum DMF and the obtained mixture was stirred for 5 min. Then, 4-aminoquinoline-diamines (1.0 mmol) was added to the reaction mixture and the stirring was continued for 5 h. The reaction end was proved by thin layer chromatography (TLC). Then, DMF was evaporated using rotary evaporator and cold water (20 mL) was added, and solid precipitates obtained were ltered and washed with cold water. The crude product was recrystallized in absolute ethanol.
N-(2-((7-Chloroquinolin-4-yl)amino)ethyl)-2-(1,3-dioxoisoindolin-2-yl)acetamide (7a 2H, -CH 2 -); 3.00-3.05 (m, 2H, -CH 2 -); 3.20-3.25 (m, 2H, -CH 2 -) 115.9, 119.34, 123.4, 126.6, 127.2, 132.1, 134.6, 138.7, 138.8, 143.3 General procedure for synthesis of C-5 secondary amine substituted N-((7-chloroquinolin-4-yl)aminoalkyl)-2-(1,3-dioxoisoindolin-2-yl)alkylamides 8a-r
N-(2-((7-
In a microwave reaction vial was added a solution of C-5 uoro substituted N-((7-chloroquinolin-4-yl)aminoalkyl)-2-(1,3-dioxoisoindolin-2-yl)alkylamides (1.0 mmol) in 0.5 mL of NMP (Nmethylpyrrolidin-2-one) and secondary amines (1.2 mmol). Aer sealing with a PTFE cap, the vessel was heated to 160 C for 5 min in the microwave reactor and the completion was ascertained using TLC. Aer completion, the contents were poured in water (20 mL) resulting in the precipitation of the desired product. The yellow product obtained was ltered and recrystallized using absolute ethanol. N-(2-((7-Chloroquinolin-4-yl)amino)ethyl)-2-(5-morpholino-1,3-dioxoisoindolin-2-yl)acetamide (8a 
Materials and methods
Bacterial strains and growth conditions M. tuberculosis mc 2 6230 (ref. 29 ) was grown at 37 C in Middlebrook 7H9 supplemented with oleic-albumin-dextrosecatalase enrichment (OADC) and 109 mM of pantothenic acid (complete 7H9).
Drug susceptibility testing
The vulnerability of M. tuberculosis mc 2 6230 to the synthesized compounds was determined as reported previously. 30 Briey, an exponentially growing culture was diluted in complete 7H9 to and OD 600 ¼ 0.01. The bacteria were then seeded in 100 mL volumes in all the wells of a 96-well plate except the rst column of wells which contained 200 mL of bacterial suspension. Compounds (stock concentration 10 mg mL À1 ) were directly added to the wells of the rst column so as to achieve a concentration of 200 mg mL À1 (or 100 mg mL À1 in cases where precipitation at the higher concentration was observed). Twofold serial dilutions were then carried out by transferring 100 mL of bacterial suspension from the rst column of wells to the second column, mixing, and repeating this procedure for each consecutive column. The plates were then placed in sealed plastic bags and incubated at 37 C. Aer 7 days of incubation, plates were visually inspected to determine the MIC, which was dened as the minimal concentration of compound at which no growth of bacteria was observed. Drug susceptibility testing was completed twice, with each compound tested in duplicate.
Isoniazid was included as a positive control.
Cytotoxicity assay
Cell viability was determined using Vero cells (ATCC, Sigma, Germany) grown in RPMI medium (Gibco, USA), supplemented with 10% decomplemented fetal calf serum, under a 5% CO 2 atmosphere. Cells were seeded in 96-well plates at a density of 2 Â 10 4 cells per well in 160 mL medium and incubated overnight at 37 C to allow cells to adhere. Compounds (dissolved in DMSO) were freshly diluted to appropriate concentrations in RPMI, so as to allow addition of 20 mL volumes of the diluted compounds to the cells that resulted in nal compound concentrations ranging from 100 mg mL À1 to 0.78 mg mL À1 . The maximum nal concentration of DMSO was 1% (v/v) and no cytotoxic effect of DMSO was observed at this concentration. Aer 24 h incubation at 37 C, 20 mL of 1 mg mL À1 resazurin (Sigma, Germany) was added to each well and the cells were incubated for an additional 3 hours at 37 C. Fluorescence was measured in a Polarstar Omega uorometer using appropriate lters (540 nm excitation and 590 nm emission wave length). Percentage survival was determined by dividing uorescence values obtained in the compound containing wells by values obtained for control wells containing cells incubated with a dilution series of DMSO and multiplying this value by 100. SDS (20%) was included as a positive control. Cytotoxic evaluation was completed twice, with each compound tested in duplicate. The IC 50 is dened as the lowest concentration of compound tested at which exactly 50% cell viability was observed and was calculated using a non-linear regression curve using Graphpad Prism 5. The SI values were determined as a function of IC 50 /MIC 99 .
